our Ly6E-targeting antibody-drug conjugate incorporating our proprietary topoisomerase 1 inhibitor payload, ZD06519. These preclinical findings demonstrate how our therapeutic approaches have the ...

"Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E ...